Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H43N13O10.3ClH |
Molecular Weight | 795.073 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.Cl.[H][C@@]1(C[C@H](O)NC(N)=N1)[C@]2([H])NC(=O)\C(NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CNC2=O)NC(=O)C[C@@H](N)CCCN)=C\NC(N)=O
InChI
InChIKey=AVXDCWXBRLUSCG-JJEOMLORSA-N
InChI=1S/C25H43N13O10.3ClH/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43;;;/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48);3*1H/b13-7-;;;/t10-,11+,12-,14-,15-,17-,18-;;;/m0.../s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C25H43N13O10 |
Molecular Weight | 685.69 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 2 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including
https://books.google.ru/books?id=JxElBQAAQBAJ&pg=PA421&lpg=PA421&dq=VIOMYCIN retrieved from Antibiotics: Origin, Nature and Properties
Tadeusz Korzybski,Zuzanna Kowszyk-Gindifer,Wlodzimierz Kurylowicz, p. 421
Curator's Comment: Description was created based on several sources, including
https://books.google.ru/books?id=JxElBQAAQBAJ&pg=PA421&lpg=PA421&dq=VIOMYCIN retrieved from Antibiotics: Origin, Nature and Properties
Tadeusz Korzybski,Zuzanna Kowszyk-Gindifer,Wlodzimierz Kurylowicz, p. 421
Viomycin is a basic peptide antibiotic, which is among the most effective agents against multidrug-resistant tuberculosis. The tuberactinomycins, such as Viomycin, target bacterial ribosomes, binding RNA and disrupting bacterial protein biosynthesis. Specifically, viomycin binds to a site on the ribosome which lies at the interface between helix 44 of the small ribosomal subunit and helix 69 of the large ribosomal subunit. The structures of this complexes suggest that the viomycin inhibits translocation by stabilizing the tRNA in the A site in the pretranslocation state.
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg/kg 1 times / day multiple, intravenous Dose: 15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 15 mg/kg, 1 times / day Co-administed with:: pyrazinamide Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: tubersulosis Age Group: 58 years Sex: M Population Size: 1 Sources: |
Other AEs: Hypomagnesemia, Hypocalcemia... |
75 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: tubersulosis Sources: |
Other AEs: Hypocalcemia, Hypokalemia... Other AEs: Hypocalcemia Sources: Hypokalemia |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypocalcemia | 15 mg/kg 1 times / day multiple, intravenous Dose: 15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 15 mg/kg, 1 times / day Co-administed with:: pyrazinamide Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: tubersulosis Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
Hypokalemia | 15 mg/kg 1 times / day multiple, intravenous Dose: 15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 15 mg/kg, 1 times / day Co-administed with:: pyrazinamide Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: tubersulosis Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
Hypomagnesemia | 15 mg/kg 1 times / day multiple, intravenous Dose: 15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 15 mg/kg, 1 times / day Co-administed with:: pyrazinamide Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: tubersulosis Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
Hypocalcemia | 75 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: tubersulosis Sources: |
|
Hypokalemia | 75 mg/kg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: tubersulosis Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Experimental studies on therapeutic effects of various combinations of antituberculosis drugs. II. Comparison of various regimens in treatment of experimental mouse tuberculosis infected with SM- and INH-resistant Schacht strain. | 1967 Jul |
|
[Clinical studies of cochleotoxicosis due to viomycin and kanamycin during tuberculostatic treatment (a prophylactic attempt)]. | 1968 |
|
Chemical studies on tuberactinomycin. 3. The chemical structure of viomycin (tuberactinomycin B). | 1972 Jul |
|
Hypocalcemia, hypomagnesemia and hypokalemia during chemotherapy of pulmonary tuberculosis. | 1972 May |
|
In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. | 1981 Sep-Oct |
|
Antibacterial activity of palmitoyltuberactinamine N and di-beta-lysylcapreomycin IIA. | 1983 Dec |
|
A Bartter's-like syndrome from capreomycin, and a similar gentamicin tubulopathy. | 1986 Mar |
|
Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. | 1993 Sep 24 |
|
Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. | 1996 Jun |
|
Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. | 2000 Feb 1 |
|
Developing a dynamic pharmacophore model for HIV-1 integrase. | 2000 Jun 1 |
|
New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method. | 2004 Jan |
|
Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. | 2005 Aug |
Sample Use Guides
Pulmunary tuberculosis: 30-75 mg/kg, intramuscularly, 14-182 days
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/209306
Viomycin at a concentration of 10 uM inhibits E. coli ribosomes to the extent of about 70% as measured in the poly (U) system, and to about 85% in a natural mRNA (R17) system.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 00:28:42 GMT 2023
by
admin
on
Sat Dec 16 00:28:42 GMT 2023
|
Record UNII |
41G0335UA0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
39750-31-7
Created by
admin on Sat Dec 16 00:28:42 GMT 2023 , Edited by admin on Sat Dec 16 00:28:42 GMT 2023
|
PRIMARY | |||
|
71587148
Created by
admin on Sat Dec 16 00:28:42 GMT 2023 , Edited by admin on Sat Dec 16 00:28:42 GMT 2023
|
PRIMARY | |||
|
41G0335UA0
Created by
admin on Sat Dec 16 00:28:42 GMT 2023 , Edited by admin on Sat Dec 16 00:28:42 GMT 2023
|
PRIMARY | |||
|
m11467
Created by
admin on Sat Dec 16 00:28:42 GMT 2023 , Edited by admin on Sat Dec 16 00:28:42 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |